Recent advances in the phencyclidine model of schizophrenia
1991/10/01 by Daniel C. Javitt, Stephen R. Zukin · 45 citations
Neuroscience · Biochemistry, Genetics and Molecular Biology · Pharmacology, Toxicology and Pharmaceutics · #Neurotransmitter Receptor Influence on Behavior #Nicotinic Acetylcholine Receptors Study #Forensic Toxicology and Drug Analysis
paper · doi:10.1176/ajp.148.10.1301
Abstract
OBJECTIVE: Phencyclidine (PCP, "angel dust") induces a psychotomimetic state that closely resembles schizophrenia. As opposed to amphetamine-induced psychosis, PCP-induced psychosis incorporates both positive (e.g., hallucinations, paranoia) and negative (e.g., emotional withdrawal, motor retardation) schizophrenic symptoms. PCP-induced psychosis also uniquely incorporates the formal thought disorder and neuropsychological deficits associated with schizophrenia. The purpose of the present paper is to review recent advances in the study of the molecular mechanisms of PCP action and to describe their implications for the understanding of schizophrenic pathophysiology. METHOD: Twenty-five papers were identified that described the clinical dose and serum and CSF levels at which PCP induces its psychotomimetic effects. The dose range of PCP-induced effects were compared to the dose range at which PCP interacts with specific molecular targets and affects neurotransmission. RESULTS: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP. At these concentrations PCP interacts selectively with a specific binding site (PCP receptor) that is associated with the N-methyl-D-aspartate (NMDA)-type excitatory amino acid receptor. Occupation of its receptor by PCP induces noncompetitive inhibition of NMDA receptor-mediated neurotransmission. Other NMDA antagonists such as the dissociative anesthetic ketamine induce PCP-like neurobehavioral effects in proportion to their potency in binding to the PCP receptor and inducing NMDA receptor inhibition. CONCLUSIONS: These findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia. The relative implications of the PCP and amphetamine models of schizophrenia are discussed in relationship to the diagnosis and etiology of schizophrenia.
Cited by
- Glutamate Receptor Dysfunction and Schizophrenia
- Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia
- Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions
- Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders
- Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms
- MK-801 impairs working memory on the Trial-Unique Nonmatch-to-Location test in mice, but this is not exclusively mediated by NMDA receptors on PV+ interneurons or forebrain pyramidal cells
- Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function
- Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)
- Altered neural oscillations are associated with improved working memory performance in schizophrenia following D-cycloserine administration
- Ketamine, at a Dose that Disrupts Motor Behavior and Latent Inhibition, Enhances Prefrontal Cortex Synaptic Efficacy and Glutamate Release in the Nucleus Accumbens
- Ketamine-Induced Hallucinations
- The layer 6b theory of attention
- Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model
- Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
- Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
- The effect of ketamine on the consolidation and extinction of contextual fear memory
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
- The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias
- Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. [europepmc]
- Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. [europepmc]
- Prefrontal dopamine D1 receptors and working memory in schizophrenia. [europepmc]
- Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. [europepmc]
- Early-stage visual processing and cortical amplification deficits in schizophrenia. [europepmc]
- A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. [europepmc]
- Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. [europepmc]
- NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. [europepmc]
- Neurophysiological biomarkers for drug development in schizophrenia. [europepmc]
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. [europepmc]
- Removing obstacles in neuroscience drug discovery: the future path for animal models. [europepmc]
- When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. [europepmc]
- Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. [europepmc]
- N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? [europepmc]
- Glutamate receptor ion channels: structure, regulation, and function. [europepmc]
- Oxidative stress in schizophrenia: an integrated approach. [europepmc]
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. [europepmc]
- Animal models of schizophrenia. [europepmc]
- Scaling brain size, keeping timing: evolutionary preservation of brain rhythms. [europepmc]
- Glutamate and dopamine in schizophrenia: an update for the 21st century. [europepmc]
- Auditory dysfunction in schizophrenia: integrating clinical and basic features. [europepmc]
- Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. [europepmc]
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. [europepmc]
- Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. [europepmc]
- Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. [europepmc]
Related